|
Title
|
Published
|
Price
|
By
Timely Data Resources
The Colorectal Cancer Executive Market Summary 2013 provides an overview of the disease and related conditions, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, information on diagnosis, staging, and pro
|
May
2013
|
$
995
|
By
Timely Data Resources
TheBladder Cancer Executive Market Summary 2013 provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers and percentages for major countries worldwide, information on diagnosis, and an overview of
|
May
2013
|
$
995
|
By
World Market Intelligence
SynopsisThe SAHG - Doha Proton Therapy Cancer Center - Qatar - Construction Project Profile contains information on the scope of the project including project overview and location. The profile also details project ownership and funding, gives a ful
|
April
2013
|
$
75
|
By
World Market Intelligence
SynopsisThe ISREC - Lausanne AGORA Cancer Center - Vaud - Construction Project Profile contains information on the scope of the project including project overview and location. The profile also details project ownership and funding, gives a full pro
|
April
2013
|
$
75
|
By
Timely Data resources
The Cervical Cancer Disease and Therapy Review provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers for major countries worldwide, information on diagnosis, and an overview of treatment.&nbs...
|
February
2013
|
$
950
|
By
Timely Data resources
The Prostate Cancer Disease and Therapy Review provides an overview of the disease and related conditions, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, and an overview of treatment.&nb...
|
February
2013
|
$
950
|
By
ICON Group International, Inc.
This econometric study covers the latent demand outlook for bladder cancer therapeutics across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Ch
|
January
2013
|
$
495
|
By
ICON Group International, Inc.
This econometric study covers the latent demand outlook for cancer therapy pharmaceuticals across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing,
|
January
2013
|
$
495
|
By
Current Partnering
The Bladder Cancer Partnering 2007-2013 provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of bladder cancer p...
|
January
2013
|
$
995
|
By
Current Partnering
The Brain Cancer Partnering 2007-2013 provides understanding and access to the brain cancer partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of brain cancer partner...
|
January
2013
|
$
995
|
By
GlobalData
Cancer Genetics, Inc. (CGI) is the leader in the field of personalized medicine. It offers cancer diagnostics and treatments tailoring the specific genetic profile of the individual. The diagnostic assays and products offered by the company are desig
|
December
2012
|
$
750
|
By
GlobalData
ONCOVEDA Cancer Research Center (Oncoveda) is a multi-discipline cancer research centre. It conducts research on early detection, monitoring, and treatment of gynecologic and urologic cancers. The company mainly focuses on developing diagnostic tool
|
December
2012
|
$
750
|
By
World Market Intelligence
SynopsisThe SBU - Stony Brook Cancer Medical Research Facility - New York - Construction Project Profile contains information on the scope of the project including project overview and location. The profile also details project ownership and funding
|
November
2012
|
$
75
|
By
World Market Intelligence
SynopsisThe MC - Mayo Clinic Phoenix Proton Cancer Therapy Center - Arizona - Construction Project Profile contains information on the scope of the project including project overview and location. The profile also details project ownership and fundi
|
October
2012
|
$
75
|
By
Venture Planning Group
This report provides an overview of the French cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.
|
October
2012
|
$
750
|
By
Venture Planning Group
This report provides an overview of the German cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.
|
October
2012
|
$
750
|
By
Venture Planning Group
This report provides an overview of the Italian cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.
|
October
2012
|
$
650
|
By
Venture Planning Group
This report provides an overview of the Japanese cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.
|
October
2012
|
$
750
|
By
Venture Planning Group
This report provides an overview of the Spanish cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.
|
October
2012
|
$
750
|
By
Venture Planning Group
This report provides an overview of the UK cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.
|
October
2012
|
$
450
|
By
Venture Planning Group
This report provides an overview of the US cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.
|
October
2012
|
$
850
|
By
GlobalData
Dana-Farber Cancer Institute, Inc. (Dana-Farber) is engaged in cancer research. The company offers treatment for different types of cancers such as breast, cutaneous, bone marrow transplant, gynecologic, gastrointestinal, genitourinary, head and neck
|
August
2012
|
$
250
|
By
GlobalData
Cancer Therapeutics CRC Pty Ltd (Ctx) is a pharmaceutical company, based in Australia. The company discovers and develops small molecule drugs for the treatment of cancer. It develops novel treatments for breast, prostate, melanoma, lung and brain ca
|
August
2012
|
$
250
|
By
GlobalData
Cancer Research Technology Limited (CRT) is a pharmaceutical company, based in the UK. The company researches, develops and commercializes oncology products, cancer therapeutics, vaccines, diagnostics and enabling technologies. It identifies and deve
|
August
2012
|
$
250
|
By
GlobalData
Advanced Cancer Therapeutics (ACT) is a biotechnology company, based in the US. The company research and develops, and commercializes novel cancer therapeutics. Its pipeline product line includes ACT-GRO-777 (DNA aptamer), PU27 (Oligo Quadruplex), PF
|
August
2012
|
$
250
|
By
Timely Data resources
The Ovarian Cancer Disease and Therapy Review provides an overview of ovarian cancerm, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, as well as information on diagnosis, and an overview of treatmen...
|
August
2012
|
$
995
|
By
World Market Intelligence
SynopsisThe IMPL - Toulouse Oncopole Cancer Research Centre - Midi-Pyrennes - Construction Project Profile contains information on the scope of the project including project overview and location. The profile also details project ownership and fundi
|
August
2012
|
$
75
|
By
Global Markets Direct
Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2012'', provides an overview of the Muscle Invasive Bladder Cancer (MIBC) therapeutic
|
July
2012
|
$
500
|
By
Global Markets Direct
Epithelial Ovarian Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Epithelial Ovarian Cancer - Pipeline Review, H2 2012'', provides an overview of the Epithelial Ovarian Cancer therapeutic pipeline. This report provides infor
|
July
2012
|
$
500
|
By
Global Markets Direct
Endobronchial Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Endobronchial Cancer - Pipeline Review, H2 2012'', provides an overview of the Endobronchial Cancer therapeutic pipeline. This report provides information on the t
|
July
2012
|
$
500
|
By
Global Markets Direct
Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2012'', provides an overview of the Transitional Cell Cancer (
|
July
2012
|
$
500
|
By
Global Markets Direct
Colon Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Colon Cancer - Pipeline Review, H2 2012'', provides an overview of the Colon Cancer therapeutic pipeline. This report provides information on the therapeutic development f
|
July
2012
|
$
500
|
By
Global Markets Direct
Metastatic Pancreatic Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Metastatic Pancreatic Cancer - Pipeline Review, H2 2012'', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provi
|
July
2012
|
$
500
|
By
Global Markets Direct
Ureter Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Ureter Cancer - Pipeline Review, H2 2012'', provides an overview of the Ureter Cancer therapeutic pipeline. This report provides information on the therapeutic developmen
|
July
2012
|
$
500
|
By
Global Markets Direct
Fallopian Tube Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Fallopian Tube Cancer - Pipeline Review, H2 2012'', provides an overview of the Fallopian Tube Cancer therapeutic pipeline. This report provides information on th
|
July
2012
|
$
500
|
By
Global Markets Direct
Endometrial Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Endometrial Cancer - Pipeline Review, H2 2012'', provides an overview of the Endometrial Cancer therapeutic pipeline. This report provides information on the therape
|
July
2012
|
$
500
|
By
Global Markets Direct
Peritoneal Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Peritoneal Cancer - Pipeline Review, H2 2012'', provides an overview of the Peritoneal Cancer therapeutic pipeline. This report provides information on the therapeuti
|
July
2012
|
$
500
|
By
Global Markets Direct
Metastatic Liver Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Metastatic Liver Cancer - Pipeline Review, H2 2012'', provides an overview of the Metastatic Liver Cancer therapeutic pipeline. This report provides information
|
July
2012
|
$
500
|
By
Global Markets Direct
Rectal Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Rectal Cancer - Pipeline Review, H2 2012'', provides an overview of the Rectal Cancer therapeutic pipeline. This report provides information on the therapeutic developmen
|
July
2012
|
$
500
|
By
Global Markets Direct
Urinary Tract Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ''Urinary Tract Cancer - Pipeline Review, H2 2012'', provides an overview of the Urinary Tract Cancer therapeutic pipeline. This report provides information on the t
|
July
2012
|
$
500
|